Business Segments · Total revenues
Oncology & Multispecialty — Total revenues
McKesson Oncology & Multispecialty — Total revenues increased by 8.0% to $13.01B in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates growth in market share, volume, or pricing, while a decrease may signal competitive pressure or loss of key contracts.
Detailed definition
This metric represents the total gross revenue generated by the Oncology and Multispecialty segment from the sale of pha...
Peer comparison
Standard top-line revenue metric for business segments in the pharmaceutical wholesale and specialty distribution industry.
Metric ID:
mck_segment_oncology_multispecialty_total_revenuesHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $9.16B | $9.49B | $12.04B | $13.01B |
| QoQ Change | — | +3.7% | +26.9% | +8.0% |
| YoY Change | — | — | +31.5% | +37.0% |
Range$9.16B – $13.01B
Avg YoY Growth+34.3%
Median YoY Growth+34.3%
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — total revenues?
- McKesson (MCK) reported oncology & multispecialty — total revenues of $13.01B in Q4 2025.
- What does oncology & multispecialty — total revenues mean?
- Total sales revenue generated by the Oncology and Multispecialty business segment.